Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
2.860
-0.080 (-2.72%)
Dec 3, 2024, 12:08 PM EST - Market open

Galmed Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for GLMD.

Analyst Consensus: n/a
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

There are currently no analyst ratings available for GLMD.

Recommendation Trends

Rating Feb '23Mar '23Apr '23May '23Jun '23Jul '23
Strong Buy 000000
Buy 000000
Hold 444440
Sell 000000
Strong Sell 000000
Total 444440

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Maxim Group
Maxim Group
Strong Buy
Upgrades
$48
Strong Buy Upgrades $48 +1,578.26% Jul 24, 2023
Maxim Group
Maxim Group
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Aug 8, 2022
Canaccord Genuity
Canaccord Genuity
Hold
Downgrades
$900$180
Hold Downgrades $900$180 +6,193.49% Aug 8, 2022
Raymond James
Raymond James
Hold
Downgrades
n/a
Hold Downgrades n/a n/a May 18, 2022
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Downgrades
n/a
Hold Downgrades n/a n/a May 3, 2022
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.32
from -30.00
EPS Next Year
-1.05
from -1.32
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
--------
Revenue Growth
--------
EPS
-174.43-243.35-237.60-127.90-30.00-1.32-1.05-1.03
EPS Growth
--------
Forward PE
--------
No. Analysts -----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202420252026202720282029
High n/a n/a n/a
Avg n/a n/a n/a
Low n/a n/a n/a

Revenue Growth

Revenue Growth 202420252026202720282029
High - - -
Avg - - -
Low - - -

EPS Forecast

EPS 2024202520262027
High -1.35 -1.08 -1.06
Avg -1.32 -1.05 -1.03
Low -1.26 -1.01 -0.99

EPS Growth

EPS Growth 2024202520262027
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.